Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix® (asciminib) showing superior major molecular response (MMR...
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched fro...
Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptaco...
Novartis cannot block generic of best-selling heart drug, US appeals court says
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' blockbuster heart drug Entresto.
Why Novartis (NVS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
2 Dividend Stocks to Buy and Hold Forever
No income investor buys shares of a dividend-paying company expecting that it will suspend its distributions at some point. Quite the contrary, dividend investors want those payouts to keep going a...
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurr...
Basel, November 27, 2024 – Novartis announced today that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment o...
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE ...
Basel, November 25, 2024 – Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Expositi...
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.
Novartis: launch of Morphosys drug by could be 2027 or later
Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further sa...
Novartis raises annual sales guidance until 2028
Novartis on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions.
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029 Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+...
Novartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Novartis (NVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wal...
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear fr...
Related Companies